Herceptin(R), Chemotherapy and Early Stage Breast Cancer

Armen Hareyan's picture
Advertisement

Results from two large randomized clinical trials for patients with HER-2 positive invasive breast cancer show that those patients with early-stage breast cancer who received Herceptin (R)(trastuzumab) in combination with chemotherapy had a significant decrease in risk for breast cancer recurrence compared with patients who received the same chemotherapy without trastuzumab. Patients are considered

Advertisement